Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00284180 · ClinicalTrials.gov registry record · Phase 2
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00284180 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 32 participants.
The verdict
NCT00284180, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This research study involves the anti-cancer medication trastuzumab and the investigational drug vinflunine. The purpose of this trials is to see if trastuzumab and vinflunine used in combination or vinflunine alone is effective in the treatment of metastatic breast cancer
Interventions
- DRUG Trastuzumab
- DRUG Vinflunine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00284180
The ClinicalTrials.gov registry entry for NCT00284180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT00284180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00284180 about?
NCT00284180 is a clinical study titled "Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer". This research study involves the anti-cancer medication trastuzumab and the investigational drug vinflunine. The purpose of this trials is to see if trastuzumab and vinflunine used in combination or vinflunine alone is effective in the treatment of metastatic breast cancer
What is the current status of trial NCT00284180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2006-01. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00284180?
The interventions under investigation include: Trastuzumab (DRUG), Vinflunine (DRUG).
Who is sponsoring clinical trial NCT00284180?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.